CorMedix Inc.
CRMD
Positions held
Your positionsCRMD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $570.55M | Enterprise value | $461.32M | Trailing P/E | 3.57 | Forward P/E | 20.91 |
| PEG | 5.20 | Price / book | 1.23 | Beta | 1.41 | Dividend yield | 0.00% |
| Revenue growth | 1.6% | Earnings growth | 6.7% | Gross margin | 90.2% | Operating margin | 42.1% |
| Profit margin | 40.5% | ROE | 54.9% | ROA | 24.6% | Debt / equity | 0.32 |
| Current ratio | 2.56 | Free cash flow | $178.14M | Analyst recommendation | strong_buy | Mean target | $15.33 |
| 52w high | $13.02 | 52w low | $6.13 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $99.3M | $127M | $129M | $104M | $39.7M | — |
| Op margin | 43.2% | 50.0% | 46.0% | 49.2% | 49.2% | — |
| Net income | $26.0M | $38.6M | $14.0M | $109M | $19.8M | — |
| Gross margin | 75.0% | 82.5% | 83.4% | 89.3% | 95.3% | — |
| Gross profit | $74.5M | $105M | $107M | $93.1M | $37.9M | — |
| Operating income | $42.9M | $63.7M | $59.1M | $51.3M | $19.5M | — |
- Revenue -22% vs prior quarter ($99M vs $127M).
- Gross margin 75% (was 82.5% prior quarter).
- Operating margin compressed to 43.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $312M | $43.5M | $0.0M | $0.1M |
| Op margin | 48.2% | -51.4% | — | -46819.9% |
| Net income | $163M | -$17.9M | -$46.3M | -$29.7M |
| Gross margin | 88.5% | 92.7% | — | 94.3% |
| Gross profit | $276M | $40.3M | $0.0M | $0.1M |
| Operating income | $150M | -$22.4M | -$49.0M | -$30.6M |
Headlines — positive tone
• [OK · fundamentals] Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...
News
2026-10-08 · CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
2026-09-23 · Oppenheimer Initiates CorMedix at Outperform With $15 Price Target
2026-09-08 · CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged
2026-09-07 · Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
2026-09-01 · CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
2026-08-31 · CorMedix (CRMD) Upgraded to Buy: Here's Why
2026-08-20 · CorMedix (CRMD) Q2 2026 Earnings Call Transcript
2026-08-20 · Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
2026-08-14 · CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says
2026-08-14 · RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating
2026-08-14 · CorMedix Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...
Price (daily)
Full chart · RSI · MACD · patterns